BACKGROUND: The Opioid-Related Symptom Distress Scale (ORSDS) is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 12 symptom-specific scores. The ORSDS was validated for outpatient laparoscopic cholecystectomy (under general anesthesia) by assessment of internal consistency, content validity, construct validity, principal components analysis, known group validity, responsiveness, and opioid dose dependency. Additional validation studies were suggested. We investigated performance characteristics and validity of the ORSDS for postoperative analgesia after 4 types of anesthetic and analgesic regimens. METHODS: The ORSDS and validation questions were administered to 4 groups of 50 orthopedic patients. Peripheral nerve blockade (Peripheral) was performed for distal upper extremity surgery; neuraxial anesthesia (Neuraxial) was performed for anterior cruciate ligament reconstruction; combined spinal-epidural anesthesia/femoral nerve block/epidural analgesia (Regional) was performed for total knee arthroplasty; and general anesthesia/IV opioids (GA) was performed for posterior lumbar spine fusion. All patients also received oral opioid analgesics. RESULTS: Median composite ORSDS scores on postoperative day 1 were 0.19 (Peripheral), 0.52 (Neuraxial), 0.51 (Regional), and 0.94 (GA). The following symptoms had median symptom-specific ORSDS scores >0: Neuraxial = drowsiness, dry mouth; Regional = dizziness, dry mouth; GA = nausea, fatigue, dizziness, drowsiness, dry mouth. Problematic symptoms (symptoms for which at least 25%of patients reported symptom-specific ORSDS scores >1) were: all groups = drowsiness, dry mouth, fatigue; Neuraxial = nausea, dizziness, itchiness; Regional = nausea, dizziness, itchiness; GA = difficulty concentrating, headache, nausea, dizziness, itchiness. High symptom-specific ORSDS scores were associated with clinically meaningful adverse events. In some cases, relevant ORSDS scores were related to activity level, patient satisfaction, and nausea and vomiting measures. Many components occurred in correlated clusters. Responsiveness statistics (the ability of an instrument to detect changes once they have occurred) were high for nausea and vomiting. Linear regression analysis indicated that opioid use was associated with composite ORSDS scores for Peripheral, Regional, and GA. CONCLUSIONS: Validity of the ORSDS was supported by predetermined validation criteria, including measures of internal consistency, content validity, construct validity, principal components analysis, known group validity, responsiveness, and correlation with opioid intake. The ORSDS is a valid tool for assessment of opioid side effects after orthopedic surgery, and can be used in clinical trials involving a wide variety of anesthetic and analgesic regimens.
BACKGROUND: The Opioid-Related Symptom Distress Scale (ORSDS) is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 12 symptom-specific scores. The ORSDS was validated for outpatient laparoscopic cholecystectomy (under general anesthesia) by assessment of internal consistency, content validity, construct validity, principal components analysis, known group validity, responsiveness, and opioid dose dependency. Additional validation studies were suggested. We investigated performance characteristics and validity of the ORSDS for postoperative analgesia after 4 types of anesthetic and analgesic regimens. METHODS: The ORSDS and validation questions were administered to 4 groups of 50 orthopedic patients. Peripheral nerve blockade (Peripheral) was performed for distal upper extremity surgery; neuraxial anesthesia (Neuraxial) was performed for anterior cruciate ligament reconstruction; combined spinal-epidural anesthesia/femoral nerve block/epidural analgesia (Regional) was performed for total knee arthroplasty; and general anesthesia/IV opioids (GA) was performed for posterior lumbar spine fusion. All patients also received oral opioid analgesics. RESULTS: Median composite ORSDS scores on postoperative day 1 were 0.19 (Peripheral), 0.52 (Neuraxial), 0.51 (Regional), and 0.94 (GA). The following symptoms had median symptom-specific ORSDS scores >0: Neuraxial = drowsiness, dry mouth; Regional = dizziness, dry mouth; GA = nausea, fatigue, dizziness, drowsiness, dry mouth. Problematic symptoms (symptoms for which at least 25%of patients reported symptom-specific ORSDS scores >1) were: all groups = drowsiness, dry mouth, fatigue; Neuraxial = nausea, dizziness, itchiness; Regional = nausea, dizziness, itchiness; GA = difficulty concentrating, headache, nausea, dizziness, itchiness. High symptom-specific ORSDS scores were associated with clinically meaningful adverse events. In some cases, relevant ORSDS scores were related to activity level, patient satisfaction, and nausea and vomiting measures. Many components occurred in correlated clusters. Responsiveness statistics (the ability of an instrument to detect changes once they have occurred) were high for nausea and vomiting. Linear regression analysis indicated that opioid use was associated with composite ORSDS scores for Peripheral, Regional, and GA. CONCLUSIONS: Validity of the ORSDS was supported by predetermined validation criteria, including measures of internal consistency, content validity, construct validity, principal components analysis, known group validity, responsiveness, and correlation with opioid intake. The ORSDS is a valid tool for assessment of opioid side effects after orthopedic surgery, and can be used in clinical trials involving a wide variety of anesthetic and analgesic regimens.
Authors: J T YaDeau; Y Lin; D J Mayman; E A Goytizolo; M M Alexiades; D E Padgett; R L Kahn; K M Jules-Elysee; A S Ranawat; D D Bhagat; K G Fields; A K Goon; J Curren; G H Westrich Journal: Br J Anaesth Date: 2015-08 Impact factor: 9.166
Authors: Jacques T YaDeau; Leonardo Paroli; Kara G Fields; Richard L Kahn; Vincent R LaSala; Kethy M Jules-Elysee; David H Kim; Stephen C Haskins; Jacob Hedden; Amanda Goon; Matthew M Roberts; David S Levine Journal: Reg Anesth Pain Med Date: 2015 Jul-Aug Impact factor: 6.288
Authors: Kethy M Jules-Elysee; Amanda K Goon; Geoffrey H Westrich; Douglas E Padgett; David J Mayman; Amar S Ranawat; Chitranjan S Ranawat; Yi Lin; Richard L Kahn; Devan D Bhagat; Enrique A Goytizolo; Yan Ma; Shane C Reid; Jodie Curren; Jacques T YaDeau Journal: J Bone Joint Surg Am Date: 2015-05-20 Impact factor: 5.284
Authors: Kethy M Jules-Elysée; Natasha A Desai; Yan Ma; Wei Zhang; Thuyvan H Luu; Stavros G Memtsoudis; Gregory A Liguori Journal: Reg Anesth Pain Med Date: 2018-01 Impact factor: 6.288
Authors: Jacques T YaDeau; Michael A Gordon; Enrique A Goytizolo; Yi Lin; Kara G Fields; Amanda K Goon; Guilherme Holck; Timothy W Miu; Lawrence V Gulotta; David M Dines; Edward V Craig Journal: Pain Med Date: 2015-12-14 Impact factor: 3.750
Authors: J T Yadeau; E A Goytizolo; D E Padgett; S S Liu; D J Mayman; A S Ranawat; M C Rade; G H Westrich Journal: Bone Joint J Date: 2013-05 Impact factor: 5.082
Authors: Mary F Chisholm; Jennifer Cheng; Kara G Fields; Robert G Marx; Daniel B Maalouf; Gregory A Liguori; Michael A Gordon; Victor M Zayas; Jacques T Yadeau Journal: Knee Surg Sports Traumatol Arthrosc Date: 2016-04-13 Impact factor: 4.342
Authors: Szymon Bialka; Maja Copik; Andrzej Daszkiewicz; Eva Rivas; Kurt Ruetzler; Lukasz Szarpak; Hanna Misiolek Journal: J Thorac Dis Date: 2018-08 Impact factor: 2.895
Authors: Andrew A Herring; Aidan A Vosooghi; Joshua Luftig; Erik S Anderson; Xiwen Zhao; James Dziura; Kathryn F Hawk; Ryan P McCormack; Andrew Saxon; Gail D'Onofrio Journal: JAMA Netw Open Date: 2021-07-01